Skip to main content

Table 1 Meaning of the different categories of the quality of evidence and of the strength of the recommendation according to the GRADE approach

From: European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

Grading of the quality of evidence

High

We are very confident that the true effect lies close to that of the estimate of the effect

Moderate

We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low

Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low

We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

Strength of the recommendation

Strong (↑↑)

the panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects

Weak (↑)

the panel concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but is not confident